Inventor · disambiguated record
Ben C. Askew
Also filed as: ASKEW BEN · ASKEW BEN C
52 granted patents·10 pending applications·607 citations·filing 1993–2023
98Inventor score
Files withSCIFLUOR LIFE SCIENCES INC21KALA PHARMACEUTICALS INC19MERCK & CO INC13OCUTERRA THERAPEUTICS INC6AMGEN INC1
Top patents by PatentIndex Score
62 records- 0196US9593114B2Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivativesSCIFLUOR LIFE SCIENCES INC·Filed 2016·Granted Mar 14, 2017·8 cites·20 claims
- 0296US9266884B2Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-y1)-3-arylpropanoic acid derivativesSCIFLUOR LIFE SCIENCES INC·Filed 2014·Granted Feb 23, 2016·14 cites·20 claims
- 0396US8901144B2Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivativesSCIFLUOR LIFE SCIENCES LLC·Filed 2014·Granted Dec 2, 2014·19 cites·14 claims
- 0496US6048861AIntegrin receptor antagonistsMERCK & CO INC·Filed 1998·Granted Apr 11, 2000·100 cites·47 claims
- 0595US9802933B2Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivativesSCIFLUOR LIFE SCIENCES INC·Filed 2016·Granted Oct 31, 2017·7 cites·17 claims
- 0695US9717729B2Fluorinated integrin antagonistsSCIFLUOR LIFE SCIENCES INC·Filed 2016·Granted Aug 1, 2017·14 cites·19 claims
- 0795US9572801B2Tetrahydronaphthyridinyl propionic acid derivatives and uses thereofSCIFLUOR LIFE SCIENCES INC·Filed 2016·Granted Feb 21, 2017·22 cites·18 claims
- 0894US10155758B2Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivativesSCIFLUOR LIFE SCIENCES INC·Filed 2017·Granted Dec 18, 2018·5 cites·17 claims
- 0994US9518053B2Fluorinated integrin antagonistsSCIFLUOR LIFE SCIENCES INC·Filed 2014·Granted Dec 13, 2016·16 cites·18 claims
- 1093US9790222B2Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereofSCIFLUOR LIFE SCIENCES INC·Filed 2016·Granted Oct 17, 2017·10 cites·19 claims
- 1193US9353122B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2014·Granted May 31, 2016·14 cites·50 claims
- 1292US11685737B2Fluorinated integrin antagonistsOCUTERRA THERAPEUTICS INC·Filed 2020·Granted Jun 27, 2023·2 cites·25 claims
- 1391US10106537B2Fluorinated integrin antagonistsSCIFLUOR LIFE SCIENCES INC·Filed 2017·Granted Oct 23, 2018·7 cites·19 claims
- 1489US10301307B2Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereofSCIFLUOR LIFE SCIENCES INC·Filed 2017·Granted May 28, 2019·5 cites·20 claims
- 1589US6017926AIntegrin receptor antagonistsMERCK & CO INC·Filed 1998·Granted Jan 25, 2000·108 cites·48 claims
- 1688US6784190B2Integrin receptor antagonistsMERCK & CO INC·Filed 2001·Granted Aug 31, 2004·17 cites·23 claims
- 1788US6232308B1Bezazepine derivatives as αv integrin receptor antagonistsMERCK & CO INC·Filed 2000·Granted May 15, 2001·34 cites·15 claims
- 1887US9877970B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2016·Granted Jan 30, 2018·4 cites·26 claims
- 1986US12497399B2Fluorinated integrin antagonistsOCUTERRA THERAPEUTICS INC·Filed 2023·Granted Dec 16, 2025·0 cites·5 claims
- 2086US11685738B2Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereofOCUTERRA THERAPEUTICS INC·Filed 2020·Granted Jun 27, 2023·1 cites·20 claims
- 2186US10398703B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2018·Granted Sep 3, 2019·3 cites·26 claims
- 2285US12286432B2Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereofOCUTERRA THERAPEUTICS INC·Filed 2023·Granted Apr 29, 2025·0 cites·20 claims
- 2385US10758539B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2019·Granted Sep 1, 2020·1 cites·23 claims
- 2483US9861634B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2016·Granted Jan 9, 2018·2 cites·21 claims
- 2583US9353123B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2014·Granted May 31, 2016·3 cites·35 claims
- 2682US9827248B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2016·Granted Nov 28, 2017·2 cites·21 claims
- 2782US9662331B23-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-onesSCIFLUOR LIFE SCIENCES INC·Filed 2015·Granted May 30, 2017·2 cites·17 claims
- 2882US5559127AFibrinogen receptor antagonistsMERCK & CO INC·Filed 1993·Granted Sep 24, 1996·41 cites·5 claims
- 2981US6413955B1Integrin receptor antagonistsMERCK & CO INC·Filed 2000·Granted Jul 2, 2002·17 cites·21 claims
- 3081US5821241AFibrinogen receptor antagonistsMERCK & CO INC·Filed 1994·Granted Oct 13, 1998·21 cites·16 claims
- 3181US2023116686A1Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3280US9988386B2Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereofKALA PHARMACEUTICALS INC·Filed 2014·Granted Jun 5, 2018·3 cites·23 claims
- 3379US9216985B23-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-onesSCIFLUOR LIFE SCIENCES INC·Filed 2014·Granted Dec 22, 2015·1 cites·19 claims
- 3478US7153862B2αv integrin receptor antagonistsMERCK & CO INC·Filed 2003·Granted Dec 26, 2006·10 cites·5 claims
- 3576US10676437B2Fluorinated 4-(substituted amino)phenyl carbamate derivativesSCIFLUOR LIFE SCIENCES INC·Filed 2018·Granted Jun 9, 2020·1 cites·17 claims
- 3675US6211184B1Integrin antagonistsMERCK & CO INC·Filed 1997·Granted Apr 3, 2001·21 cites·16 claims
- 3774US11369611B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2020·Granted Jun 28, 2022·0 cites·9 claims
- 3874US5981546AIntegrin antagonistsMERCK & CO INC·Filed 1997·Granted Nov 9, 1999·45 cites·17 claims
- 3974US2021393641A1Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4073US10308647B2Fused imidazole derivatives as IDO/TDO inhibitorsSCIFLUOR LIFE SCIENCES INC·Filed 2016·Granted Jun 4, 2019·1 cites·15 claims
- 4173US2021246132A1Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivativesSCIFLUOR LIFE SCIENCES INC·Filed 2020·Application pending·0 cites
- 4272US10966987B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2019·Granted Apr 6, 2021·0 cites·21 claims
- 4372US2021380588A1Novel Compounds and Uses ThereofKALA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4470US6693101B2αv integrin receptor antagonistsMERCK & CO INC·Filed 2001·Granted Feb 17, 2004·4 cites·1 claims
- 4570US5852045AFibrinogen receptor antagonistsMERCK & CO INC·Filed 1996·Granted Dec 22, 1998·15 cites·13 claims
- 4669US10954244B2Compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2019·Granted Mar 23, 2021·0 cites·20 claims
- 4768US10285991B2Therapeutic compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2017·Granted May 14, 2019·0 cites·26 claims
- 4867US10351570B2Compounds and uses thereofKALA PHARMACEUTICALS INC·Filed 2018·Granted Jul 16, 2019·0 cites·25 claims
- 4967US7393852B2Piperazine derivatives and methods of useAMGEN INC·Filed 2004·Granted Jul 1, 2008·3 cites·42 claims
- 5067US2019263810A1Fluorinated integrin antagonistsSCIFLUOR LIFE SCIENCES INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →